

XIVth International Workshop

of the German CLL Study Group

April 18th – 20th 2024

Balloni Cologne (Germany)

Scientific Lead

Michael Hallek, Cologne

Program Committee

Othman Al-Sawaf, Cologne
Barbara Eichhorst, Cologne
Kirsten Fischer, Cologne
Michael Hallek, Cologne

Young Investigator Meeting 2024

Petra Langerbeins, Cologne
Deborah Stephens, Chapel Hill
Loïc Ysebaert, Toulouse

YIM 2024
DCLLSG
YOUNG INVESTIGATOR MEETING ON CLL



The European Board for Accreditation in Hematology (EBAH) has certified this event with 8.5 points and the Ärztekammer Nordrhein with 10 (7 plus 3) points.



Thursday, April 18th 2024

Brauerei zur Malzmühle
Heumarkt 6 | 50667 Köln

06.00 – 07.30 p.m. Strategy commission (closed session)

07.00 – 10.00 p.m. Welcome reception

07.45 – 08.15 p.m. **Opening Keynote Lecture**
Immune function in patients with CLL A P Kater

08.15 – 10.00 p.m. Working Dinner

Friday, April 19th 2024

BALLONI Hallen
Ehrenfeldgürtel 96 | 50823 Köln

08.00 – 09.00 a.m. CLL-RT2 Investigator Meeting (closed session)

09.00 – 09.20 a.m. Check-In

09.20 – 09.30 a.m. Welcome M Hallek

Young Investigators' Meeting (YIM)

09.30 – 11.00 a.m. YIM Session I: Clinical & Translational Research *Chairs: P Langerbeins, L Ysebaert*

09.30 – 09.45 a.m. Ibrutinib lead-in followed by venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia I Romano

09.45 – 10.00 a.m. Incidence of Richter transformation in patients with chronic lymphocytic leukemia (CLL): a cohort study evaluating different therapeutic eras P J Hampel

10.00 – 10.15 a.m. Prevalence and clinical impact of clonal hematopoiesis in chronic lymphocytic leukemia R Moia

10.15 – 10.30 a.m. Preclinical efficacy of the BCL2i venetoclax combined with MEKi cobimetinib or SYKi entospletinib in BTKi-refractory CLL patients harboring BTK mutations S Martindale

10.30 – 10.45 a.m. Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia I Ashworth

10.45 – 11.00 a.m. The Gene Expression Landscape of BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia Exposed by Shallow Depth RNA Sequencing T H L Do

11.00 – 11.30 a.m.	Coffee & Tea	
11.30 – 01.00 p.m.	YIM Session II: Translational & Basic Research	<i>Chairs: D Stephens, M Hallek</i>
11.30 – 11.45 a.m.	TLR9 signaling is a potential tumor escape mechanism following B-cell receptor targeted treatments in subsets of	E Kennedy
11.45 – 12.00 a.m.	BH3 Profiling Identifies Anti-Apoptotic Dependencies and Therapeutic Vulnerabilities in Primary Richter Transformation (RT) Cells and in a Genetically-Engineered Murine Model of RT	N Javidi-Sharifi
12.00 – 12.15 p.m.	LYN kinase activity and its regulator CSK are key players in CLL supporting macrophages	V Kohlhas
12.15 – 12.30 p.m.	Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition	K Mashima
12.30 – 12.45 p.m.	Role of G protein-coupled receptor kinase 2 (GRK2) in the localization and activation of leukemic cells	C Cassarino
12.45 – 13.00 p.m.	Rps15-S138F mutation results in translational errors underlying onset of chronic lymphocytic leukemia	N Ruthen
01.00 – 01.45 p.m.	Lunch	
01.45 – 03.20 p.m.	German CLL Study Group studies	<i>Chairs: P Staber, K Fischer</i>
Phase II/III trials completed		
01.45 – 01.55 p.m.	CLL13 – Minimal Residual Disease: status and outcome	M Ritgen
01.55 – 02.05 p.m.	CLL12 CLL13 CLL14 – Genetic subgroups: different studies, same findings?	E Tausch
Ongoing trials		
02.05 – 02.10 p.m.	CLL ReVenG	M Davids
02.10 – 02.15 p.m.	CLL16	N Kutsch
02.15 – 02.20 p.m.	CLL17	O Al-Sawaf
02.20 – 02.30 p.m.	Discussion	Plenum
Ongoing trials with results		
02.30 – 02.35 p.m.	CLLRT1	B Eichhorst
02.35 – 02.40 p.m.	CLLFrail	F Simon

02.40 – 02.50 p.m.	Discussion	Plenum
Planned trials		
02.50 – 02.55 p.m.	CLL18	P Cramer
02.55 – 03.00 p.m.	CLLRT2	S Stilgenbauer
03.00 – 03.05 p.m.	Shall we address the tumor microenvironment?	A vom Stein
03.05 – 03.10 p.m.	Bendamustine debulking – yes or no?	J v Tresckow
03.10 – 03.20 p.m.	Discussion	Plenum
03.20 – 03.50 pm Coffee & Tea		
03.50 – 04.50 p.m.	Session I: Genomics and biology of CLL	<i>Chairs: R Guièze, C Herling</i>
03.50 – 04.05 p.m.	Genomic Map of CLL	BA Knisbacher
04.05 – 04.20 p.m.	Richter Transformation	F Nadeu
04.20 – 04.35 p.m.	<i>TP53</i> and beyond	P Robbe
04.35 – 04.50 p.m.	Genetic and epigenetic evolution	R Rosenquist
04.50 – 05.50 p.m.	YIM Session III: Guided Poster Walk with Coffee & Tea	<i>Chairs: D Stephens, L Ysebaert, P Langerbeins</i>
04.50 – 05.00 p.m.	Adaptation of chronic lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway	L Terzi di Bergamo
05.00 – 05.10 p.m.	Combined therapy of endocytosis inhibitors and a novel glycoengineered anti-ROR1 antibody to enhance antibody-dependent cellular cytotoxicity (ADCC) against chronic lymphocytic leukemia	K Hasan
05.10 – 05.20 p.m.	A Comparative Study of Different Macrophage Feeder Systems for the Support of Chronic Lymphocytic Leukemia Survival	H Jestrabek
05.20 – 05.30 p.m.	CAR T cells generated from CLL patients are characterized by determinants of immune dysfunction that may be positively modulated by treatment with targeted agents	F Perutelli
05.30 – 05.40 p.m.	Venetoclax resistant cells are sensitive to anti-CD20 monoclonal antibodies.	V J Sarapura Martinez
05.40 – 05.50 p.m.	Utility of the international chronic lymphocytic leukemia prognostic index in front-line treatment with targeted drugs	S Robrecht

05.50 – 06.20 p.m.	AbbVie Satellite Symposium	S Stilgenbauer
Time limited treatment regimens in CLL – Present or Future?		
06.20 – 06.50 p.m.	AstraZeneca Satellite Symposium	<i>Chair: C Herling</i>
	Pattern of Resistance in CLL and its Clinical Implications	O Al-Sawaf
06.50 – 07.40 p.m. Flying Dinner		
07.40 – 07.50 p.m.	Introduction	M Hallek
07.50 – 08.20 p.m.	Keynote Lecture	J Woyach
08.20 – 10.00 p.m. Get together		

Saturday, April 20th 2024

BALLONI Hallen
Ehrenfeldgürtel 96 | 50823 Köln

08.00 – 09.00 a.m.	CLL18 Kick-Off Meeting (closed session)	
09.00 – 09.15 a.m.	Welcome	M Hallek
09.15 – 10.00 a.m.	Session II: Treatment of CLL	<i>Chairs: M Davids, L Scarfò</i>
09.15 – 09.30 a.m.	Selecting a first-line treatment – what do we know, what do we need, what is standard?	T Munir
09.30 – 09.45 a.m.	Relapsed CLL – is it just second first-line?	P Thompson
09.45 – 10.00 a.m.	Double Refractory (BTKi and BCL2i) – what comes next?	M Hallek
10.00 – 10.30 a.m.	BeiGene Satellite Symposium	L Fallowfield
	Mental health in patients with CLL	C M Wendtner
10.30 – 11.00 a.m. Coffee & Tea		
11.00 – 11.30 a.m.	Janssen Satellite Symposium	<i>Chair: M Trepel</i>
	CLL therapy today and tomorrow	P Ghia
11.30 – 12.15 p.m.	Session III: Daily challenges in CLL management	<i>Chairs: P Thornton, T Kipps</i>
11.30 – 11.45 a.m.	Autoimmune conditions	M Coscia
11.45 – 12.00 p.m.	Infections	L Scarfò
12.00 – 12.15 p.m.	Richter Transformation	R Guièze

12.15 – 12.30 p.m. YIM Award

*Chairs: D Stephens,
L Ysebaert, P Langerbeins*

12.30 – 01.30 p.m. Lunch

01.30 – 02.00 p.m.	Lilly Satellite Symposium	J v Tresckow
	Latest CLL data – ready for clinical routine?	H Huber
02.00 – 03.00 p.m.	Session IV: Perspectives	<i>Chairs: D Rossi, J Brown</i>
02.00 – 02.15 p.m.	Novel targets	A Danilov
02.15 – 02.30 p.m.	Cellular and bispecific therapies	F Bosch
02.30 – 02.45 p.m.	Prognostic & predictive factors	I Ahn
02.45 – 03.00 p.m.	Dream your study	S Parikh
03.00 – 03.15 p.m.	Closing remarks	M Hallek

We would like to thank **AbbVie Deutschland GmbH & Co. KG**, **AstraZeneca GmbH**, **BeiGene Germany GmbH**, **Janssen-Cilag GmbH** and **Lilly Deutschland GmbH** for their kind support of this meeting with Sponsorship Package A (Platin Sponsors | €70,000 each) and **Roche Pharma AG** with Sponsorship Package B (Gold Sponsor | €40,000). **Bristol-Myers Squibb GmbH & Co. KGaA** and **Prelude Therapeutics, Inc.** are supporting the conference with Sponsorship Package D (Bronze Sponsors | €10,000 each), **MSD Sharp & Dohme GmbH** is contributing €5,000 (Copper Sponsor) to the International GCLLSG workshop. The sponsors' contributions will be used for event management, website, venue, catering and working lunches, hotel accommodation, travel expenses (of speakers, moderators, strategy committee members), video reports, certification, insurance, printing materials and technical equipment. The organizers, the scientific lead and the speakers confirm that the event is product-neutral. Any conflicts of interest of the speakers will be disclosed prior to the presentation.



On behalf of the German CLL Study Group (GCLLSG) and the Kompetenznetz Maligne Lymphome e.V. (KML) this event is organized by:



KARO - KML Academic Research Organisation GmbH

Gleueler Str. 176-178 | D-50935 Köln | info@k-aro.de | <https://k-aro.de>